{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T21:32:25Z","timestamp":1649021545831},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1007\/s00059-014-4162-6","type":"journal-article","created":{"date-parts":[[2014,10,30]],"date-time":"2014-10-30T11:28:45Z","timestamp":1414668525000},"page":"808-813","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antithrombozyt\u00e4re Therapie nach akutem Koronarsyndrom"],"prefix":"10.1007","volume":"39","author":[{"given":"C.B.","family":"Olivier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Diehl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Bode","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Moser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,11,1]]},"reference":[{"key":"4162_CR1","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(06)68770-9","volume":"367","author":"Lopez","year":"2006","unstructured":"Lopez AD, Mathers CD, Ezzati M et al (2006) Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 367:1747\u20131757","journal-title":"Lancet"},{"key":"4162_CR2","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1056\/NEJMra0801082","volume":"359","author":"Furie","year":"2008","unstructured":"Furie B, Furie BC (2008) Mechanisms of thrombus formation. N Engl J Med 359:938\u2013949","journal-title":"N Engl J Med"},{"key":"4162_CR3","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s11239-013-0918-8","volume":"37","author":"Wang","year":"2013","unstructured":"Wang WE, Wang H, Wang X et al (2013) A transition of P2Y antagonists for acute coronary syndrome: benefits, risks and costs. J Thromb Thrombolysis 37:102\u2013106","journal-title":"J Thromb Thrombolysis"},{"key":"4162_CR4","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1160\/TH12-06-0430","volume":"108","author":"Kristensen","year":"2012","unstructured":"Kristensen SD, Grove EL, Hvas AM (2012) P2Y12 inhibitors in acute coronary syndromes: how do we choose the best drug for our patients? Thromb Haemost 108:203\u2013205","journal-title":"Thromb Haemost"},{"key":"4162_CR5","unstructured":"Windecker S, Kolh P, Alfonso F et al (2014) 2014 ESC\/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J [Epub ahead of print]"},{"key":"4162_CR6","doi-asserted-by":"crossref","unstructured":"Olivier CB, Schnabel K, Brandt C et al (2014) A high ratio of ADP-TRAP induced platelet aggregation is associated more strongly with increased mortality after coronary stent implantation than high conventional ADP induced aggregation alone. Clin Res Cardiol [Epub ahead of print]","DOI":"10.1007\/s00392-014-0737-8"},{"key":"4162_CR7","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1160\/TH09-06-0418","volume":"103","author":"Sofi","year":"2010","unstructured":"Sofi F, Marcucci R, Gori AM et al (2010) Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis. Thromb Haemost 103:841\u2013848","journal-title":"Thromb Haemost"},{"key":"4162_CR8","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1056\/NEJMoa0909475","volume":"363","author":"CURRENT-OASIS","year":"2010","unstructured":"CURRENT-OASIS 7 Investigators, Mehta SR, Bassand JP et al (2010) Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 363:930\u2013942","journal-title":"N Engl J Med"},{"key":"4162_CR9","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1160\/TH13-06-0508","volume":"111","author":"Olivier","year":"2014","unstructured":"Olivier CB, Diehl P, Schnabel K et al (2014) Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry. Thromb Haemost 111:266\u2013272","journal-title":"Thromb Haemost"},{"key":"4162_CR10","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jacc.2010.02.072","volume":"56","author":"Angiolillo","year":"2010","unstructured":"Angiolillo DJ, Saucedo JF, Deraad R et al (2010) Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. J Am Coll Cardiol 56:1017\u20131023","journal-title":"J Am Coll Cardiol"},{"key":"4162_CR11","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1160\/TH09-07-0482","volume":"103","author":"Montalescot","year":"2010","unstructured":"Montalescot G, Sideris G, Cohen R et al (2010) Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study. Thromb Haemost 103:213\u2013223","journal-title":"Thromb Haemost"},{"key":"4162_CR12","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.jacc.2010.03.100","volume":"56","author":"Storey","year":"2010","unstructured":"Storey RF, Angiolillo DJ, Patil SB et al (2010) Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol 56:1456\u20131462","journal-title":"J Am Coll Cardiol"},{"key":"4162_CR13","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","volume":"120","author":"Gurbel","year":"2009","unstructured":"Gurbel PA, Bliden KP, Butler K et al (2009) Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET\/OFFSET study. Circulation 120:2577\u20132585","journal-title":"Circulation"},{"key":"4162_CR14","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/eurheartj\/ehm545","volume":"29","author":"Wallentin","year":"2008","unstructured":"Wallentin L, Varenhorst C, James S et al (2008) Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 29:21\u201330","journal-title":"Eur Heart J"},{"key":"4162_CR15","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1016\/j.jacc.2007.07.058","volume":"50","author":"Storey","year":"2007","unstructured":"Storey RF, Husted S, Harrington RA et al (2007) Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 50:1852\u20131856","journal-title":"J Am Coll Cardiol"},{"key":"4162_CR16","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1093\/eurheartj\/ehi877","volume":"27","author":"Jernberg","year":"2006","unstructured":"Jernberg T, Payne CD, Winters KJ et al (2006) Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 27:1166\u20131173","journal-title":"Eur Heart J"},{"key":"4162_CR17","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045\u20131057","journal-title":"N Engl J Med"},{"key":"4162_CR18","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"Wiviott","year":"2007","unstructured":"Wiviott SD, Braunwald E, McCabe CH et al (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001\u20132015","journal-title":"N Engl J Med"},{"key":"4162_CR19","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1161\/CIRCULATIONAHA.107.740324","volume":"116","author":"Wiviott","year":"2007","unstructured":"Wiviott SD, Trenk D, Frelinger AL et al (2007) Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 116:2923\u20132932","journal-title":"Circulation"},{"key":"4162_CR20","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1161\/CIRCULATIONAHA.108.791061","volume":"118","author":"Wiviott","year":"2008","unstructured":"Wiviott SD, Braunwald E, Angiolillo DJ et al (2008) Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 118:1626\u20131636","journal-title":"Circulation"},{"key":"4162_CR21","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1161\/CIRCULATIONAHA.108.857722","volume":"119","author":"Pena","year":"2009","unstructured":"Pena A, Collet JP, Hulot JS et al (2009) Can we override clopidogrel resistance? Circulation 119:2854\u20132857","journal-title":"Circulation"},{"key":"4162_CR22","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/jama.295.13.joc60034","volume":"295","author":"Kastrati","year":"2006","unstructured":"Kastrati A, Mehilli J, Neumann FJ et al (2006) Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 295:1531\u20131538","journal-title":"JAMA"},{"key":"4162_CR23","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.jacc.2009.05.025","volume":"54","author":"O","year":"2009","unstructured":"O\u2019Donoghue M, Antman EM, Braunwald E et al (2009) The efficacy and safety of prasugrel with and without a glycoprotein IIb\/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. J Am Coll Cardiol 54:678\u2013685","journal-title":"J Am Coll Cardiol"},{"key":"4162_CR24","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs289","volume":"33","author":"Steg","year":"2012","unstructured":"Steg PG, James SK, Atar D et al (2012) ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 33:2569\u20132619","journal-title":"Eur Heart J"},{"key":"4162_CR25","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jacc.2010.07.012","volume":"56","author":"Bellemain-Appaix","year":"2010","unstructured":"Bellemain-Appaix A, Brieger D, Beygui F et al (2010) New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: a meta-analysis. J Am Coll Cardiol 56:1542\u20131551","journal-title":"J Am Coll Cardiol"},{"key":"4162_CR26","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0140-6736(10)61088-4","volume":"376","author":"Mehta","year":"2010","unstructured":"Mehta SR, Tanguay JF, Eikelboom JW et al (2010) Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 376:1233\u20131243","journal-title":"Lancet"},{"key":"4162_CR27","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0140-6736(09)60441-4","volume":"373","author":"Montalescot","year":"2009","unstructured":"Montalescot G, Wiviott SD, Braunwald E et al (2009) Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 373:723\u2013731","journal-title":"Lancet"},{"key":"4162_CR28","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jcin.2014.01.160","volume":"7","author":"Udell","year":"2014","unstructured":"Udell JA, Braunwald E, Antman EM et al (2014) Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38). JACC Cardiovasc Interv 7:604\u2013612","journal-title":"JACC Cardiovasc Interv"},{"key":"4162_CR29","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jacc.2012.03.030","volume":"60","author":"Smith","year":"2012","unstructured":"Smith PK, Goodnough LT, Levy JH et al (2012) Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. J Am Coll Cardiol 60:388\u2013396","journal-title":"J Am Coll Cardiol"},{"key":"4162_CR30","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1161\/CIRCULATIONAHA.109.927582","volume":"122","author":"Steg","year":"2010","unstructured":"Steg PG, James S, Harrington RA et al (2010) Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation 122:2131\u20132141","journal-title":"Circulation"},{"key":"4162_CR31","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/j.jacc.2009.01.053","volume":"53","author":"De","year":"2009","unstructured":"De Luca G, Ucci G, Cassetti E et al (2009) Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-analysis. J Am Coll Cardiol 53:1668\u20131673","journal-title":"J Am Coll Cardiol"},{"key":"4162_CR32","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMoa013404","volume":"346","author":"Stone","year":"2002","unstructured":"Stone GW, Grines CL, Cox DA et al (2002) Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 346:957\u2013966","journal-title":"N Engl J Med"},{"key":"4162_CR33","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1056\/NEJM200106213442503","volume":"344","author":"Montalescot","year":"2001","unstructured":"Montalescot G, Barragan P, Wittenberg O et al (2001) Platelet glycoprotein IIb\/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 344:1895\u20131903","journal-title":"N Engl J Med"},{"key":"4162_CR34","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1001\/jama.290.12.1593","volume":"290","author":"Neumann","year":"2003","unstructured":"Neumann FJ, Kastrati A, Pogatsa-Murray G et al (2003) Evaluation of prolonged antithrombotic pretreatment (\u201ecooling-off\u201c strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial. JAMA 290:1593\u20131599","journal-title":"JAMA"},{"key":"4162_CR35","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMoa0706816","volume":"358","author":"Ellis","year":"2008","unstructured":"Ellis SG, Tendera M, Belder MA de et al (2008) Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 358:2205\u20132217","journal-title":"N Engl J Med"},{"key":"4162_CR36","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0140-6736(08)61235-0","volume":"372","author":"Van","year":"2008","unstructured":"Van\u2019t Hof AW, Ten Berg J, Heestermans T et al (2008) Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet 372:537\u2013546","journal-title":"Lancet"},{"key":"4162_CR37","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","volume":"358","author":"Stone","year":"2008","unstructured":"Stone GW, Witzenbichler B, Guagliumi G et al (2008) Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 358:2218\u20132230","journal-title":"N Engl J Med"},{"key":"4162_CR38","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/CIRCULATIONAHA.108.818617","volume":"119","author":"Mehilli","year":"2009","unstructured":"Mehilli J, Kastrati A, Schulz S et al (2009) Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial. Circulation 119:1933\u20131940","journal-title":"Circulation"},{"key":"4162_CR39","first-page":"e78","volume":"61","author":"O","year":"2013","unstructured":"O\u2019Gara PT, Kushner FG, Ascheim DD et al (2013) 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 61:e78\u2013e140","journal-title":"J Am Coll Cardiol"},{"key":"4162_CR40","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","volume":"358","author":"Mehta","year":"2001","unstructured":"Mehta SR, Yusuf S, Peters RJ et al (2001) Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358:527\u2013533","journal-title":"Lancet"}],"container-title":["Herz"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-014-4162-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00059-014-4162-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-014-4162-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T15:52:40Z","timestamp":1558540360000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00059-014-4162-6"}},"subtitle":["Differenzialtherapie und Dauer"],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["4162"],"URL":"https:\/\/doi.org\/10.1007\/s00059-014-4162-6","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11]]}}}